Open AccessPrognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors
Author(s) -
Chun Wang,
Zhaomei Mu,
Zhong Ye,
Zhenchao Zhang,
Maysa Abu-Khalaf,
Daniel P. Silver,
Juan Palazzo,
Geetha Jagannathan,
Frederick M. Fellin,
Saveri Bhattacharya,
Rebecca Jaslow,
Theodore N. Tsangaris,
Adam C. Berger,
Manish Neupane,
Terrence P. Cescon,
Ana María López,
Kaelan Yao,
Weelic Chong,
Brian Lu,
Ronald E. Myers,
Lifang Hou,
Qiang Wei,
Bingshan Li,
Massimo Cristofanilli,
Hushan Yang
Publication year - 2020
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-020-05662-x
Subject(s) - medicine , hazard ratio , oncology , breast cancer , proportional hazards model , confidence interval , stage (stratigraphy) , univariate analysis , cancer , progression free survival , multivariate analysis , chemotherapy , paleontology , biology
Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2 - /cHER2 + can benefit from anti-HER2 targeted therapies.